Nucleus Platform Enhancements
Severe-to-Profound Sensorineural Hearing Loss
Continuous DevelopmentActive
Key Facts
Indication
Severe-to-Profound Sensorineural Hearing Loss
Phase
Continuous Development
Status
Active
Company
About Cochlear
Cochlear Limited is a mission-driven medical device leader with a singular focus on treating moderate-to-profound hearing loss. The company has achieved a dominant global market position, serving over 750,000 recipients with its clinically validated, life-changing implant systems. Its strategy is built on continuous innovation within its core Nucleus and bone conduction platforms, deep clinical and customer support networks, and leveraging its installed base through recurring revenue from sound processor upgrades. This approach has established a powerful, durable brand and a sustainable financial model.
View full company profileTherapeutic Areas
Other Severe-to-Profound Sensorineural Hearing Loss Drugs
| Drug | Company | Phase |
|---|---|---|
| Marvel CI Platform Commercialization & Enhancement | Advanced Bionics | Commercial |
| Nucleus® CI632 Slim Modiolar Electrode | Cochlear | Commercial |